ArticleCancer science2023

Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.

Hirokazu Taniguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.